GUOTAI HAITONG SECURITIES·2026-03-05 07:20Investment Rating - The report rates the industry as "Overweight" [4] Core Insights - The report provides a monthly tracking of global innovative drugs, highlighting advancements and investment opportunities in relevant frontier areas [2] - CagriSema's head-to-head data underperformed expectations, leading Novo Nordisk to accelerate the development of four next-generation weight loss assets [7][12] - The PD-1/VEGF dual antibody market is projected to exceed $100 billion, with several products expected to achieve peak sales of over $10 billion [19] - PROTAC and molecular glue technologies are showing positive progress across autoimmune, oncology, and CNS fields, with significant market potential [27] - Small nucleic acids are advancing towards multiple major indications, including weight loss and HBV treatment [27] Summary by Sections Weight Loss - Novo Nordisk's REDEFINE 4 study showed CagriSema resulted in a weight loss of 23.0% over 84 weeks compared to Tirzepatide's 25.5%, failing to meet non-inferiority expectations [7][8] - The company attributes the study's failure to the unusually high performance of Tirzepatide, suggesting that the open-label design may have biased participants [7] - Following the disappointing results, Novo Nordisk is expected to expedite the development of four next-generation weight loss assets [12] PD-1/VEGF Dual Antibodies - The PD-1/VEGF dual antibody market is anticipated to grow significantly, driven by longer treatment durations and survival benefits compared to PD-1 monotherapy [19] - The HARMONi-3 study has completed enrollment of 600 patients, with plans for an interim analysis in Q2 2026 [22] - The combination of PD-1/VEGF with new therapies like RAS inhibitors and ADCs is expected to expand treatment options and market reach [19] PROTAC/Molecular Glue - The report highlights the optimistic outlook for targeted protein degradation in autoimmune diseases, with promising early results from Kymera's KT-621 and Monte Rosa's NEK7 [27][28] - NEK7's mechanism targets upstream processes in inflammation, potentially offering a differentiated approach compared to existing therapies [28] - The early studies indicate competitive performance in reducing hsCRP levels, suggesting significant therapeutic advantages [31] Small Nucleic Acids - Early research on ARO-INHBE and ARO-ALK7 suggests potential for competitive weight loss effects and safety profiles when combined with low-dose GLP-1 [27] - The successful phase 3 results of bepirovirsen for HBV treatment are expected to be disclosed at EASL, with a focus on real-world data [27] In Vivo CAR-T - Eli Lilly's acquisition of Orna for $2.4 billion underscores the growing strategic interest in in vivo CAR-T therapies [27] - The report anticipates more clinical trial data in 2026 to validate the differentiation of in vivo CAR-T approaches [27]